Evidence map›Paper›PMID 39191826›Full record

ArticleScientific reports2024

Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models.

Chia-Chin Wu, Licai Huang, Zhongting Zhang, Zhenlin Ju, Xingzhi Song, E Anders Kolb, Wendong Zhang, Jonathan Gill, Min Ha, Malcolm A Smith and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chia-Chin WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Licai HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhongting ZhangPediatric Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhenlin JuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xingzhi SongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
E Anders KolbNemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, DE, USA.
Wendong ZhangPediatric Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jonathan GillPediatric Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Min HaDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Malcolm A SmithCancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Peter HoughtonDepartment of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Christopher L MortonDepartment of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Raushan KurmashevaGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
John MarisChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Yael MosseChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Yiling LuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Richard GorlickPediatric Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hannah C BeirdDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hccheung@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Osteosarcoma: Patient Derived Xenograft Preclinical TestingU01CA199221 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Richard G. Gorlick · 2015 to 2026
$3.8M
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver CancerU01CA263981 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Raushan Kurmasheva · 2021 to 2026
$3.2M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
$726k
National Cancers Institute 130100 90 100300 52 MDGRN 00012944 1111NCI NIH HHS P30 CA016672NCI NIH HHS R50 CA221675NCI NIH HHS U01 CA199221NCI NIH HHS U01 CA263981Sheikh Mohamed Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research 101739
6 · The paper itself

Abstract

Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes in the past few decades. The need for models to test novel therapies is especially great in this disease since it is both rare and does not respond to most therapies. To address this, an NCI-funded consortium has characterized and utilized a panel of patient-derived xenograft models of osteosarcoma for drug testing. The exomes, transcriptomes, and copy number landscapes of these models have been presented previously. This study now adds whole genome sequencing and reverse-phase protein array profiling data, which can be correlated with drug testing results. In addition, four additional osteosarcoma models are described for use in the research community.

Indexed as

Bone NeoplasmsOsteosarcomaXenograft Model Antitumor AssaysAnimalsDisease Models, AnimalHumansMiceProtein Array AnalysisTranscriptomeWhole Genome Sequencing

Identifiers

PMID39191826
PMCPMC11350124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.